Vaginal hysteropexy showed no clear difference in prolapse on examination (Stage 2 or above) ‐ Any recurrent prolapse compared with sacral hysteropexy (uterine prolapse) (moderate certainty).
It is very uncertain whether vaginal hysteropexy changes mesh exposure (1‐4 years) compared with sacral hysteropexy (uterine prolapse) (very low certainty).
Vaginal procedure probably leads to higher surgery for recurrent prolapse compared with sacral colpopexy (vault prolapse) (moderate certainty).
Vaginal hysteropexy showed no clear difference in painful intercourse ‐ De novo dyspareunia compared with sacral hysteropexy (uterine prolapse) (moderate certainty).
Vaginal procedure probably leads to higher prolapse on examination (Stage 2 or above) ‐ Any recurrent prolapse compared with sacral colpopexy (vault prolapse) (moderate certainty).
Vaginal procedure showed no clear difference in intraoperative Visceral injury compared with sacral colpopexy (vault prolapse) (moderate certainty).
Vaginal procedure probably leads to higher bladder Function ‐ Stress incontinence compared with sacral colpopexy (vault prolapse) (moderate certainty).
Vaginal procedure showed no clear difference in painful intercourse ‐ Dyspareunia compared with sacral colpopexy (vault prolapse) (low certainty).
It is very uncertain whether vaginal hysterectomy changes awareness of prolapse compared with sacral hysteropexy/cervicopexy (uterine prolapse) (very low certainty).
The review found no eligible studies for this question.
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).
Fixed tooth-borne Hyrax expander showed no clear difference in molar expansion compared with bonded expander plate (acrylic); GRADE not reported.
Topical triamcinolone acetonide may leads to lower adverse effects compared with topical tacrolimus (low certainty).
Topical clobetasol propionate showed no clear difference in pain (mean VAS score) compared with topical tacrolimus; GRADE not reported.
It is very uncertain whether topical clobetasol propionate changes clinical resolution compared with topical tacrolimus (very low certainty).